Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder. A Cohort Study in the UK

Pharmacotherapy - United States
doi 10.1002/phar.2121
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Wiley

Related search

Exposure to Antimuscarinic Medications for Treatment of Overactive Bladder and Risk of Lung Cancer and Colon Cancer

Clinical Epidemiology
Epidemiology
2019English

Drugs Used to Treat Pediatric Emergencies

Pediatrics
Child HealthPediatricsPerinatology
2019English

Individual Variation of Response to Drugs

1937English

Bladder Sensations in Male and Female Overactive Bladder Patients Compared to Healthy Volunteers: A Sensation-Related Bladder Diary Evaluation

Scandinavian Journal of Urology
UrologyNephrology
2019English

Factors Associated With Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE)

Advances in Therapy
MedicinePharmacology
2019English

Drugs Can Be Used to Treat More Than Disease

Nature
Multidisciplinary
2008English

Effects of Anticholinergic Drugs Used for the Therapy of Overactive Bladder on P-Glycoprotein Activity

Biological and Pharmaceutical Bulletin
MedicinePharmacologyPharmaceutical Science
2019English

Botulinum Toxin-A for the Treatment of Overactive Bladder: UK Contributions

Journal of Clinical Urology
SurgeryUrology
2013English

Cardiovascular Risk: A UK Priority--It's Time to Act

Heart
2003English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy